X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Strides Arcolab with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES SHASUN LTD vs PIRAMAL ENTERPRISES - Comparison Results

STRIDES SHASUN LTD    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES SHASUN LTD PIRAMAL ENTERPRISES STRIDES SHASUN LTD/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 33.9 8.9 381.3% View Chart
P/BV x 0.9 2.9 30.7% View Chart
Dividend Yield % 1.1 0.8 132.3%  

Financials

 STRIDES SHASUN LTD   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    STRIDES SHASUN LTD
Mar-17
PIRAMAL ENTERPRISES
Mar-17
STRIDES SHASUN LTD/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs1,2752,095 60.8%   
Low Rs9181,025 89.6%   
Sales per share (Unadj.) Rs389.6492.8 79.1%  
Earnings per share (Unadj.) Rs28.072.6 38.5%  
Cash flow per share (Unadj.) Rs48.994.7 51.6%  
Dividends per share (Unadj.) Rs4.5021.00 21.4%  
Dividend yield (eoy) %0.41.3 30.5%  
Book value per share (Unadj.) Rs303.1862.5 35.1%  
Shares outstanding (eoy) m89.42172.56 51.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.2 88.9%   
Avg P/E ratio x39.221.5 182.3%  
P/CF ratio (eoy) x22.416.5 136.1%  
Price / Book Value ratio x3.61.8 200.0%  
Dividend payout %16.128.9 55.6%   
Avg Mkt Cap Rs m98,036269,194 36.4%   
No. of employees `0005.84.0 144.5%   
Total wages/salary Rs m5,88117,939 32.8%   
Avg. sales/employee Rs Th6,005.921,190.3 28.3%   
Avg. wages/employee Rs Th1,014.04,470.1 22.7%   
Avg. net profit/employee Rs Th431.23,120.0 13.8%   
INCOME DATA
Net Sales Rs m34,83485,037 41.0%  
Other income Rs m1,6862,338 72.1%   
Total revenues Rs m36,52087,374 41.8%   
Gross profit Rs m6,42834,991 18.4%  
Depreciation Rs m1,8723,817 49.0%   
Interest Rs m2,26920,310 11.2%   
Profit before tax Rs m3,97313,202 30.1%   
Minority Interest Rs m01,699 0.0%   
Prior Period Items Rs m40-   
Extraordinary Inc (Exp) Rs m-1,006-100 1,010.8%   
Tax Rs m4702,281 20.6%   
Profit after tax Rs m2,50112,520 20.0%  
Gross profit margin %18.541.1 44.8%  
Effective tax rate %11.817.3 68.5%   
Net profit margin %7.214.7 48.8%  
BALANCE SHEET DATA
Current assets Rs m38,16587,590 43.6%   
Current liabilities Rs m30,402185,578 16.4%   
Net working cap to sales %22.3-115.2 -19.3%  
Current ratio x1.30.5 266.0%  
Inventory Days Days7731 249.2%  
Debtors Days Days10448 219.7%  
Net fixed assets Rs m37,639108,523 34.7%   
Share capital Rs m894345 259.1%   
"Free" reserves Rs m26,210148,481 17.7%   
Net worth Rs m27,105148,826 18.2%   
Long term debt Rs m16,377144,957 11.3%   
Total assets Rs m81,168482,394 16.8%  
Interest coverage x2.81.7 166.7%   
Debt to equity ratio x0.61.0 62.0%  
Sales to assets ratio x0.40.2 243.5%   
Return on assets %5.96.8 86.4%  
Return on equity %9.28.4 109.7%  
Return on capital %12.112.0 100.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m13,46515,001 89.8%   
Fx outflow Rs m4,0765,150 79.1%   
Net fx Rs m9,3899,851 95.3%   
CASH FLOW
From Operations Rs m2,881-100,393 -2.9%  
From Investments Rs m-7,051-24,202 29.1%  
From Financial Activity Rs m3,382135,705 2.5%  
Net Cashflow Rs m-78811,110 -7.1%  

Share Holding

Indian Promoters % 27.7 52.9 52.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 4.0 945.0%  
FIIs % 8.6 26.6 32.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 16.5 157.0%  
Shareholders   56,241 93,274 60.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES SHASUN LTD With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  DISHMAN PHARMA  TTK HEALTHCARE  

Compare STRIDES SHASUN LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Lower; Metal & Realty Stocks Fall(Closing)

Indian share markets ended lower today amid weak global cues. At the closing bell, the BSE Sensex finished lower by 262 points.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES SHASUN LTD SHARE PRICE


Jun 19, 2018 (Close)

TRACK STRIDES SHASUN LTD

  • Track your investment in STRIDES SHASUN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES SHASUN LTD

STRIDES SHASUN LTD 8-QTR ANALYSIS

COMPARE STRIDES SHASUN LTD WITH

MARKET STATS